Contract drug manufacturer Catalent warns of hit from costs, low production

This post was originally published on this site

The company also said its Chief Financial Officer Thomas Castellano had left Catalent and named company insider Ricky Hopson as his replacement.

Catalent’s shares were down 15% at $53.80 in premarket trading.

The company said it experienced “productivity issues” at its gene therapy manufacturing site in Harmans, Maryland, and faced similar issues at its drug product and drug substance manufacturing facilities in Bloomington, Indiana and Brussels, Belgium.

Catalent said it had taken a number of measures at the facilities, including management and operational changes, to address the issues.